AbbVie Inc. (ABBV) — ESG & Values Scores

Environment story

AbbVie discloses a Scope 1&2 (market-based) GHG reduction target of 42% by 2030 versus a baseline, with 32.4% achieved as of 2024 — a credible operational (non-offset) trajectory, though the target year falls after 2045 threshold logic is moot since no formal net-zero year is disclosed, triggering a deduction. Scope 3 (supply-chain/product-use) emissions data are not disclosed in the reviewed filings, another deduction driver. Generic disclosure of environmental liabilities tied to hazardous-material handling in manufacturing and distribution logistics is noted but no specific, quantified controversy (e.g., a named toxic-spill or water-depletion event) appears in the source documents, so only a modest severity deduction is applied. This is descriptive research output, not investment advice.

Criticisms on file

Generic disclosure of environmental liabilities related to hazardous material handling in manufacturing and distribution logistics (no specific incident quantified)
Source: AbbVie 10-K (FY2025), Item 1A Risk Factors, 'Other factors' section

Disclosed initiatives

Scope 1&2 Emissions Reduction Target

Global target to reduce absolute Scope 1 and 2 (market-based) GHG emissions by 42.0% by 2030; 32.4% reduction achieved as of 2024, per company ESG disclosures referenced in the 2026 proxy statement.

Operational (non-offset) reduction progress toward interim 2030 milestone
TCFD/SASB-Aligned Reporting

AbbVie has issued TCFD-aligned climate disclosures since 2022 and SASB-aligned reporting in its ESG Action Report since 2021.

Improved transparency on climate-related risk

Social story

AbbVie's disclosed CEO-to-median-employee pay ratio of 192:1 falls below the 200:1 rubric threshold. No documented union-suppression activity, strikes, or NLRB complaints appear in the reviewed filings. Leadership/board diversity percentages are not numerically disclosed in the reviewed documents, so no diversity-based deduction is applied absent verified data. No supply-chain human-rights hazards (e.g., conflict minerals) are applicable given AbbVie's pharmaceutical manufacturing model. This is descriptive research output, not investment advice.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Patient Assistance Program

Over 210,000 U.S. patients provided medicine at no cost through AbbVie's patient assistance program in 2025.

Expanded patient access to medicines
Employee Engagement

91% employee survey response rate in 2025, with 84% indicating engagement.

Workforce engagement signal
AbbVie Foundation Week of Possibilities

Nearly 14,000 employees across 58 countries contributed over 44,000 volunteer hours in 2025.

Community engagement

Governance story

AbbVie maintains a single-class common stock structure (no dual-class voting), and board independence stands at approximately 92% (12 of 13 directors), well above the 75% threshold. The company is pursuing elimination of its supermajority voting requirement via a 2026 management proposal. Governance deductions stem from AbbVie's active legal posture in the Mississippi 340B pricing litigation (seeking to enjoin a state consumer-protection-oriented law, ultimately denied by the Fifth Circuit) and from multiple active/recent antitrust and pricing-related legal proceedings, including the AndroGel antitrust matter (liability finding upheld though damages overturned) and a since-dismissed excessive-pricing suit brought by the Pharmaceutical Accountability Foundation in the Netherlands. This is descriptive research output, not investment advice.

Criticisms on file

AndroGel antitrust litigation — antitrust liability finding against Abbott/AbbVie upheld regarding delayed generic entry (damages overturned)
Source: Reuters, 'Column: Here's what AbbVie doesn't want you to know about its sham Androgel patent,' July 25, 2023
Pharmaceutical Accountability Foundation excessive-pricing lawsuit (Netherlands), dismissed on standing grounds
Source: Pharmaceutical Accountability Foundation press release, July 9, 2025
340B pricing litigation — Fifth Circuit affirmed denial of AbbVie's injunction against Mississippi state law protecting 340B contract pharmacy arrangements
Source: American Hospital Association news summary, July 14, 2025, citing Mississippi District Court ruling

Disclosed initiatives

Elimination of Supermajority Voting

2026 management proposal to remove 80% supermajority voting thresholds from AbbVie's charter and bylaws, previously submitted 2018-2025.

Would lower barrier for future shareholder-driven governance amendments
Lead Independent Director Role

Robust Lead Independent Director responsibilities in place since AbbVie's 2013 inception; Roxanne Austin appointed 2024.

Provides independent counterbalance to combined Chair/CEO role

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of AbbVie Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open AbbVie Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO) Abbott Laboratories (ABT)